// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























7277 Abstracts

IMPROVEDD Score: Addition of D-Dimer to the IMPROVE Score Improves Venous Thromboembolism Risk Stratification. An APEX Trial Substudy

Gerald Chi - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Biomarkers of Exposures and Cardiovascular Toxicity of Smokeless Tobacco Products

Iris Zeller - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Fibrinogen (IV)

Risk of Arterial and Venous Thromboembolism in Patients With Atrial Fibrillation or Flutter: A 10-Year Nationwide Cohort Study

Erzsebet Hovath-Puho - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Comparative Effectiveness and Clinical Safety Between Dabigatran, Rivaroxaban, and Warfarin

Ho-Min Chen - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

rivaroxaban

Trends and Outcomes of Outpatient Management of Pulmonary Embolism in a Real World Setting

Janie Coulombe - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Risk Factors of Thromboembolism in Patients With Left Ventricular Noncompaction

Shunsuke Eguchi - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration

Usman Baber - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Thrombogenicity of Platinum-chromium Everolimus-eluting Stent is Comparable Low to that of Cobalt-chromium Everolimus-eluting Stent in the Subacute Phase of Acute Myocardial Infarction

Osamu Iida - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Edoxaban for the Prevention of Thromboembolism in Patients With Bioprosthetic Valves in ENGAGE AF-TIMI 48

Raffaele De Caterina - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Edoxaban

Acute Right Ventricular Failure After Successful Opening of Chronic Total Occlusion in Right Coronary Artery

Anson Lee - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Prasugrel

Rivaroxaban, but Not PAR-2 Antagonist, Attenuates Cardiac Remodeling Due to Intermittent Hypoxia in Sleep Apnea Model Mice

Ayumi Fujiwara - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Thrombolysis versus Surgery for Obstructive Prosthetic Valve Thrombosis

Emrah Bayam - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Benzene Exposure Is Associated With Increased CVD Risk, Hyperlipidemia, and Decreased Circulating Angiogenic Cells in Humans and Mice

Natasha DeJarnett - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Perioperative Venous Thromboembolism occurs outside the operating room

Michael F O'Connor - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Role and Factors Associated With Removal of Retrievable Inferior Vena Cava Filter in Venous Thromboembolism

Keiji Hirooka - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

Characterizing the Practice of Vascular Medicine at an Academic Medical Center

Nancy Nguyen - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methadone hydrochloride

Rivaroxaban and Apixaban for Treatment of Venous Thrombosis of Atypical Location

Dawid Janczak - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

rivaroxaban

A Low Burden Mouse Auricle Model for Venous Research

Larissa Pfisterer - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Bortezomib

Ovarian Vein Thrombosis: Risk Factors and Outcomes

Kevin Cohoon - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Long-term Clinical Outcomes After Everolimus-eluting Stent Implantation in Patients With Acute Myocardial Infarction in Comparison With Sirolimus-eluting Stent

Kazushige Kadota - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

Copyright © 2026. QuantiNova All rights reserved